Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00094887 · ClinicalTrials.gov registry record · Phase 2

Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises

A Phase 2 study of Anemia, Sickle Cell, sponsored by Mallinckrodt.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target
11
Study locations

NCT00094887: Completed Phase 2 study of Anemia, Sickle Cell, sponsored by Mallinckrodt.

NCT00094887 is a Phase 2 study of Anemia, Sickle Cell that has completed, run by Mallinckrodt. The registered enrollment target is 150 participants, above the 109-participant average among 17 other Anemia, Sickle Cell trials with a reported enrollment target (38% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00094887, a Phase 2 study of Anemia, Sickle Cell, has completed, sponsored by Mallinckrodt.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target
11
Study locations

Study Summary

This study will examine whether nitric oxide (NO) gas can reduce the time it takes for pain to go away in patients who are in sickle cell crisis. NO is important in regulating blood vessel dilation, and consequently, blood flow. The gas is continuously produced by cells that line the blood vessels. It is also transported from the lungs by hemoglobin in red blood cells. Patients 10 years of age or older with sickle cell disease (known SS, S-beta-thalassemia or other blood problems causing sickle cell disease) may be eligible for this study. Patients whose disease is due to hemoglobin (Hgb) SC are excluded. Candidates are screened with blood tests and a chest x-ray to look at the lungs and heart. Participants are admitted to the hospital in a pain crisis. They are evaluated and then randomly assigned to receive one of two treatments: 1) standard treatment plus NO, or 2) standard treatment plus placebo. The placebo used in this study is nitrogen, a gas that makes up most of the air we breathe and is not known to help in sickle cell disease. For the first 8 hours of the study, patients receive placebo or NO through a facemask. The mask may be taken off for 5 minutes every hour and for not more than 20 minutes to eat a meal. After the first 8 hours, the gas is delivered through a nasal cannula (small plastic tubing that rests under the nose) that may be taken off only while showering or using the restroom. Patients are questioned about the severity of their pain when they start the study and then every few hours while they are in the hospital. Their vital signs (temperature, breathing rate, and blood pressure) and medicines are checked. Patients will breathe the gas for a maximum of 3 days, but will stay hospitalized until the patient feels well enough to go home. Patients are followed up about 1 month after starting the study by a return visit to the hospital or by a phone call.

Primary Outcome

VOC resolution was defined by all of the following conditions: * Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best) * Freedom from parenteral narcotic use, * Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis, * Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Nitric Oxide

Study Locations (11)

Maryland

  • Johns Hopkins University - Baltimore
  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Childrens Hospital, Boston - Boston

Pennsylvania

  • St. Christopher's Hospital for Children - Philadelphia
  • Childrens Hospital, Pittsburgh - Pittsburgh

Alabama

  • University of Alabama - Birmingham

California

  • Children's Hospital Oakland - Oakland

Colorado

  • Colorado Sickle Cell Treatement and Research Center - Aurora

District of Columbia

  • Howard University Hospital - Washington D.C.

Ohio

  • Case Western Reserve University Hospital - Cleveland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2004-10
Est. Completion 2008-12
Phase Phase 2
Mallinckrodt

69 total trials

What the finished NCT00094887 record still lists

NCT00094887 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 109-participant average among 17 other Anemia, Sickle Cell trials with a reported enrollment target (38% higher).

The record links to 1 condition, with Anemia, Sickle Cell appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00094887 lists 11 locations in 8 states (Maryland, Massachusetts, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT00094887 about?

NCT00094887 is a clinical study titled "Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises". This study will examine whether nitric oxide (NO) gas can reduce the time it takes for pain to go away in patients who are in sickle cell crisis. NO is important in regulating blood vessel dilation, and consequently, blood flow. The gas is continuously produced by cells that line the blood vessels. ...

What is the current status of trial NCT00094887?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-10. Estimated completion is 2008-12.

What conditions does trial NCT00094887 study?

This clinical trial studies the following conditions: Anemia, Sickle Cell.

What interventions are being tested in trial NCT00094887?

The interventions under investigation include: Placebo (DRUG), Nitric Oxide (DRUG).

Who is sponsoring clinical trial NCT00094887?

This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00094887 being conducted?

This trial has 11 study locations across Alabama, California, Colorado, District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anemia, Sickle Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00094887's enrollment target sits among peer trials

150 5th of 17 higher than 12 of 17 other Anemia, Sickle Cell trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anemia, Sickle Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00094887, the US trial registry maintained by the National Library of Medicine. NCT00094887 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.